The efficacy and toxicity of TRT on metastatic NSCLC in patients treated with targeted therapy and chemoimmunotherapy.
2/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
523 patients with metastatic NSCLC from 2019–2024.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Treatment strategies should be personalized based on molecular subtype and toxicity risk. [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s00432-026-06470-4.
OpenAlex 토픽 ·
Lung Cancer Treatments and Mutations
Brain Metastases and Treatment
Gastrointestinal Tumor Research and Treatment
[PURPOSE] The role of thoracic radiotherapy (TRT) combined with first-line systemic therapy for metastatic non-small cell lung cancer (NSCLC) remains controversial.
APA
Lishan Xue, Jinquan Yao, et al. (2026). The efficacy and toxicity of TRT on metastatic NSCLC in patients treated with targeted therapy and chemoimmunotherapy.. Journal of cancer research and clinical oncology, 152(4). https://doi.org/10.1007/s00432-026-06470-4
MLA
Lishan Xue, et al.. "The efficacy and toxicity of TRT on metastatic NSCLC in patients treated with targeted therapy and chemoimmunotherapy.." Journal of cancer research and clinical oncology, vol. 152, no. 4, 2026.
PMID
41961169 ↗
Abstract 한글 요약
[PURPOSE] The role of thoracic radiotherapy (TRT) combined with first-line systemic therapy for metastatic non-small cell lung cancer (NSCLC) remains controversial. Its application is not routinely recommended due to inconsistent efficacy and toxicity risks. This study aims to identify specific patients most likely to benefit from TRT in advanced NSCLC.
[METHODS] A cohort included 523 patients with metastatic NSCLC from 2019–2024. Kaplan–Meier curves and log-rank tests were used to analyze progression-free survival (PFS) and overall survival (OS). Risk factors were identified using univariate and multivariate Cox regression analysis.
[RESULTS] The entire cohort median OS was 60 months and median PFS was 22 months. TRT improved both PFS (25 vs. 13 months, < 0.001) and OS (Not Reached [NR] vs. 46 months, < 0.001). In the targeted therapy group, TRT improved PFS (27 vs. 13 months, < 0.001) and OS (NR vs. 47 months, < 0.001). In the chemoimmunotherapy group, TRT improved OS (NR vs. 41 months, = 0.042) but not PFS (18 vs. 14 months, = 0.115). Exploratory analysis found TRT increased hematologic toxicity (e.g., ≥ grade 2 lymphopenia: 67.18% vs. 11.33%, < 0.001) and pneumonitis (any grade: 71.31% vs. 17.68%; ≥ grade 2: 17.83% vs. 4.88%, both < 0.001). Multivariate analysis identified Planning target volume (PTV) as an independent negative predictor for PFS in the TRT group ( = 0.003).
[CONCLUSION] Adding TRT to first-line systemic therapy improves survival in metastatic NSCLC. Treatment strategies should be personalized based on molecular subtype and toxicity risk.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s00432-026-06470-4.
[METHODS] A cohort included 523 patients with metastatic NSCLC from 2019–2024. Kaplan–Meier curves and log-rank tests were used to analyze progression-free survival (PFS) and overall survival (OS). Risk factors were identified using univariate and multivariate Cox regression analysis.
[RESULTS] The entire cohort median OS was 60 months and median PFS was 22 months. TRT improved both PFS (25 vs. 13 months, < 0.001) and OS (Not Reached [NR] vs. 46 months, < 0.001). In the targeted therapy group, TRT improved PFS (27 vs. 13 months, < 0.001) and OS (NR vs. 47 months, < 0.001). In the chemoimmunotherapy group, TRT improved OS (NR vs. 41 months, = 0.042) but not PFS (18 vs. 14 months, = 0.115). Exploratory analysis found TRT increased hematologic toxicity (e.g., ≥ grade 2 lymphopenia: 67.18% vs. 11.33%, < 0.001) and pneumonitis (any grade: 71.31% vs. 17.68%; ≥ grade 2: 17.83% vs. 4.88%, both < 0.001). Multivariate analysis identified Planning target volume (PTV) as an independent negative predictor for PFS in the TRT group ( = 0.003).
[CONCLUSION] Adding TRT to first-line systemic therapy improves survival in metastatic NSCLC. Treatment strategies should be personalized based on molecular subtype and toxicity risk.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1007/s00432-026-06470-4.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Becotatug Vedotin in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multicenter, Phase IIa Trial.
- Efficacy and Safety of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer With Lymph Node Metastasis.
- Tumor microenvironment and immunometabolic reprogramming in pancreatic ductal adenocarcinoma: Barriers and breakthroughs in immunotherapy.
- Correction to "Targeted Delivery of AR-V7 siRNA with Bivalent PSMA Aptamers Effectively Suppresses the Growth of Enzalutamide-Resistant Prostate Cancer".
- Autophagy regulates anti-angiogenic property of lenvatinib in thyroid cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy.
- Novel roles of SETD2 in tumor metabolism and immunotherapy: a systematic review and meta-analysis.
- Negative trial but positive lesson: reframing immunotherapy resistance from one-size-fits-all to precision strategies.
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy.
- Copper-enriched zinc peroxides induced cuproptosis through concurrent metabolic and oxidative dysregulation for boosting immunotherapy in colorectal cancer.